Medical University of South Carolina

Medical University of South Carolina logo
🇺🇸United States
Ownership
Private
Established
1955-01-01
Employees
10K
Market Cap
-
Website
https://www.muschealth.com

Magnetic Brain Stimulation for the Treatment of Adult Depression

First Posted Date
2005-09-08
Last Posted Date
2018-12-28
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
190
Registration Number
NCT00149838
Locations
🇺🇸

Columbia University, New York, New York, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Brain Stimulation Laboratory, Medical University of South Carolina, Charleston, South Carolina, United States

and more 1 locations

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Phase 2
Terminated
Conditions
First Posted Date
2005-07-11
Last Posted Date
2018-05-11
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
1
Registration Number
NCT00118196
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

First Posted Date
2005-02-08
Last Posted Date
2018-11-05
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
23
Registration Number
NCT00103376
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

🇺🇸

South Carolina Oncology Associates, PA, Columbia, South Carolina, United States

🇺🇸

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

and more 1 locations

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

First Posted Date
2004-12-09
Last Posted Date
2024-01-31
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
20
Registration Number
NCT00099086

Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 1
Terminated
Conditions
First Posted Date
2004-11-09
Last Posted Date
2018-04-10
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
36
Registration Number
NCT00096304
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

Phase 1
Completed
Conditions
First Posted Date
2004-09-13
Last Posted Date
2018-05-16
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
49
Registration Number
NCT00003344
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer

First Posted Date
2004-09-08
Last Posted Date
2018-07-12
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
10
Registration Number
NCT00090870
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

First Posted Date
2004-08-05
Last Posted Date
2018-07-16
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
9
Registration Number
NCT00089102
Locations
🇺🇸

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

First Posted Date
2004-08-05
Last Posted Date
2018-07-12
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
16
Registration Number
NCT00089128
Locations
🇺🇸

Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath